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ABSTRACT: Insulin-like growth factors 1 and 2 (IGF-1 and -2, respectively) are protein
hormones involved not only in normal growth and development but also in life span
regulation and cancer. They exert their functions mainly through the IGF-1R or by
binding to isoform A of the insulin receptor (IR-A). The development of IGF-1 and IGF-2
antagonists is of great clinical interest. Mutations of A4 and A8 sites of human insulin lead
to disproportionate eﬀects on hormone IR binding and activation. Here, we systematically
modiﬁed IGF-1 sites 45, 46, and 49 and IGF-2 sites 45 and 48, which correspond, or are
close, to insulin sites A4 and A8. The IGF-1R and IR-A binding and autophosphorylation
potencies of these analogues were characterized. They retained the main IGF-1R-related
properties, but the hormones with His49 in IGF-1 and His48 in IGF-2 showed
signiﬁcantly higher aﬃnities for IR-A and for IR-B, being the strongest IGF-1- and IGF-2-like binders of these receptors ever
reported. All analogues activated IR-A and IGF-1R without major discrepancies in their binding aﬃnities. This study revealed
that IR-A and IGF-1R contain speciﬁc sites, likely parts of their so-called sites 2′, which can interact diﬀerently with speciﬁcally
modiﬁed IGF analogues. Moreover, a clear importance of IGF-2 site 44 for eﬀective hormone folding was also observed. These
ﬁndings may facilitate novel and rational engineering of new hormone analogues for IR-A and IGF-1R studies and for potential
medical applications.
Two insulin-like growth factors, IGF-1 and IGF-2, togetherwith insulin, are members of a family of small protein
hormones that share common evolutionary origins,1−4 having
similar primary (Figure 1) and three-dimensional structures.5
They regulate a wide spectrum of key physiological events, with
insulin being responsible mainly for broad, metabolic control,6
while IGF-1 and IGF-2 are growth factors involved primarily in
the development and growth of mammals.5 The role of IGF-1
is relatively well studied,7−9 but physiological functions of IGF-
2 are much less understood,10 despite emerging evidence of its
impact on the central nervous system.11,12
IGF-1, IGF-2, and insulin exert their activities by binding to
diﬀerent but highly homologous (∼75%), ∼450 kDa (αβ)2
dimeric tyrosine-kinase receptors: IGF-1 receptor (IGF-1R)
and insulin receptor (IR).13−15 IR exists in two isoforms, IR-A,
and IR-B, with distinct biochemical properties16,17 and a
speciﬁc tissue distribution. IR-B is a predominant IR form in
liver, while muscle and adipose tissues contain both isoforms at
diﬀerent ratios. IR-A is predominant in brain, fetus, and
lymphatic tissues and is considered mainly as a “mitogenic”
form of the IR, in contrast to IR-B that is considered as the
main “metabolic” receptor for insulin.16−18 A high degree of
homology of these receptors results in a signiﬁcant cross-
binding of insulin and both IGFs to IR-A and IGF-1R,19 and
hence some overlapping biological responses to binding of
these ligands.20,21
The binding of insulin and IGFs to these receptors triggers
two major signaling pathways that are initiated by the
autophosphorylation of tyrosines within their intracellular
tyrosine kinase domains.22 The phosphoinositide 3-kinase
(PI3K)/Akt pathway leads to the metabolic, glycemic responses
and eﬀects of the hormone:receptor complex, but it is also
important for growth and protein synthesis.23 The Ras/ERK
main pathway involves activation of the Ras/Raf/MAPK/
ERK1/2 cascade, which mediates proliferative eﬀects through
gene transcription regulation.21 Whereas insulin signals mainly
via both IR isoforms,24 IGF-1 and IGF-2 promote mitogenic
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signaling through IGF-1R, and, importantly, similar mitogenic
stimulation may result from binding of IGF-2 to IR-A.25 The
complexity of insulin/IGF signaling is ampliﬁed further by the
heterodimerization of IGF-1R and IR-A, and the presence of
hybrid receptors that can be eﬀectively activated by IGF-1, but
not by insulin.26,27 Moreover, the bioavailability of free IGF-1
and IGF-2 for receptor signaling is modulated by a family of
high-aﬃnity IGF binding proteins 1−6 (IGFBP 1−6,
respectively),28,29 and the circulation level of IGF-2 is also
aﬀected by a structurally distinct, and presumably nonsignaling,
insulin-like growth factor type 2 receptor (IGF-2R), also known
as the mannose 6-phosphate receptor.30 The equilibrium of all
individual components and the appropriate function of the
entire insulin/IGF system are essential for a proper functioning
of the organism.31
In recent years, the role of the IGF/insulin system in cancer
development and growth has been widely studied.10,31,32
Substantial eﬀorts have been focused on the development of
new anti-IGF-1R-directed therapies, mostly tyrosine-kinase
(TK) inhibitors and antireceptor antibodies.33 However, the
results of clinical trials were not satisfactory,34 because of either
the toxicity of the TK-targeting drugs or an increasing overlap
and takeover of IGF-1R signaling pathways by the IR. The lack
of progress in addressing one of the key hallmarks of cancer
underlines the need for new anticancer therapies that would
exploit alternative, and speciﬁc, targets of the insulin/IGF axis.
Here, a high-aﬃnity/no-eﬃcacy IGF-based IGF-1 analogue, i.e.,
selective antagonist of the IGF-1R, should represent a
promising new strategy for combating IGF-1R-related malig-
nancies.
To date, no IGF-like peptide antagonists of the IGF-1R have
been identiﬁed. However, peptides with good IR/IGF-1R
binding and antagonistic properties toward these receptors
were discovered by a phage-display technique.35,36 Whittaker et
al.37 showed that a combination of GluA4His and ThrA8His
mutations of human insulin results in insulin analogues with
native IR binding aﬃnity but poor eﬃcacy, an impaired ability
to stimulate autophosphorylation of IR, and downstream Akt
activation. They also proposed that surfaces involving insulin
GluA4 and IR Asp707 could be behind the mechanism of
receptor activation.
Interestingly, insulin acidic GluA4 is preserved by its
equivalent Asp45 and Glu44 in IGF-1 and IGF-2, respectively
(Figure 1). However, insulin-neutral Gln A5 is replaced by
Glu46, and Glu45 in corresponding sites of IGF-1 and IGF-2.
In addition, Asp707 of IR α-CT is replaced by a neutral Asn694
in the IGF-1R α-CT segment (Figure 2).
These correlations and trends between positions A4 and A5
in insulin and their IGFs equivalent 45 and 46 (in IGF-1) and
44 and 55 (in IGF-2) sites prompted us to study (i) the impact
Figure 1. Comparison of the primary sequences of human IGF-1, IGF-2, and insulin. The organization of IGF-1 and IGF-2 into B, C, A, and D
domains is shown below the sequences. Insulin A and B chains correspond to IGF A and B domains, respectively. The homologous regions are
highlighted in gray, and the residues mutated in this study are highlighted in yellow.
Figure 2. Receptor-bound structures of human insulin and human IGF-1 overlaid with human IGF-2. (A) Complex (4OGA)38 of human insulin
sitting on the IR-L1 domain and IR α-CT peptide. Insulin is colored cyan, the L1 domain light gray, and α-CT pink. Side chains of insulin residues
GluA4, GlnA5, ThrA8, and α-CT Asp707 are shown and labeled. (B) Complex (4XSS)39 of human IGF-1 (violet) bound to the IR-L1 domain (light
gray) and the IGF-1R α-CT peptide (orange). Side chains of IGF-1 residues Asp45, Glu46, and Phe49 mutated in this study and α-CT Asn694 are
shown and labeled. The complex is overlaid with the NMR structure of human IGF-2 (5L3L),40 which is colored light green. Mutated IGF-2 residues
Glu44, Glu45, and Phe48 and α-CT Asp694 are also shown and labeled.
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of the mutations of these residues on receptor aﬃnities and
potencies of these hormones, and (ii) whether such mutations
can generate signiﬁcant IGF-1R-speciﬁc antagonists, with
potential anticancer clinical applications. A series of 14 IGF-1
and IGF-2 analogues mutated at these sites have been designed
and made, and their binding to IGF-1R and IR-A and abilities
to activate the receptors were characterized. Some of these
mutations were also combined with the Phe49His mutation in
IGF-1 and the Phe48His mutation in IGF-2, as it has been
shown that insulin-corresponding mutation ThrA8His signiﬁ-
cantly increased the IR-A binding potency of this ana-
logue.37,41−46
Despite the results for the analogues studied here not
showing any antagonism, they revealed interesting properties of
new IGF-1 and IGF-2 mutants that can interact diﬀerently with
receptors for insulin and IGF-1. This could indicate new
directions for a rational engineering of these hormones.
■ MATERIALS AND METHODS
Cloning and Production of IGF-1 and IGF-2 Ana-
logues. As in our previously published research,40 both human
IGF-1 (UniprotKB entry P05019 amino acids 49−118) and
human IGF-2 (UniprotKB entry P01344 amino acids 25−91)
have been cloned into a modiﬁed pRSFDuet-1 expression
vector (kindly provided by E. Bourǎ from the Institute of
Organic Chemistry and Biochemistry in Prague) as a fusion
with an N-terminally His6-tagged GB1 protein and TEV
protease cleavage site. An additional N-terminal glycine residue
(Gly−1) was incorporated into IGF-1 to enable cleavage by
TEV protease (Glu-Asn-Leu-Tyr-Phe-Gln↓Gly). In contrast to
our previous study,40 the TEV protease cleavage site for the
IGF-2 expression construct was modiﬁed to Glu-Asn-Leu-Tyr-
Phe-Gln↓Ala, cleavage (↓) of which resulted in a native
hormone with an N-terminal alanine. [D45H], [D45N],
[D45A], [E46H], [E46Q], and [E46A] mutations in IGF-1
analogues were obtained by the standard site-directed muta-
genesis protocol (SDM)47 using appropriate mutagenic primers
(listed in Table S1). After sequence veriﬁcation, the mutant
fragments were reintroduced into the expression vector.
Additional [D45N+E46Q], [F49H], [E46H+F49H], [E46Q
+F49H], and [D45N+E46Q+F49H] mutations in IGF-1
analogues and in all cloned IGF-2 analogues were introduced
either by the overlap-extension polymerase chain reaction (OE
strategy in Table S1),48 using speciﬁc primers as ﬂanking
master primers and subsequent recloning into expression
vector, or by the standard site-directed mutagenesis as
mentioned above (SDM strategy in Table S1), using
appropriate mutagenic primers.
We succeeded in expressing and purifying all planned IGF-1
analogues. However, only three IGF-2 analogues (with
mutations [E45Q], [F48H], and [E45Q+F48H]) were
successfully produced. A list of successfully expressed
constructs along with primers used for mutagenesis is provided
as Table S1.
All successfully constructed analogues were produced,
puriﬁed, and characterized, using the procedures described by
Hexnerova et al.40 The purity of all tested analogues was >95%
(and controlled by reverse phase high-performance liquid
chromatography analyses and high-resolution mass spectrom-
etry spectra).
Biological Characterization of IGF-1 and IGF-2
Analogues. Binding aﬃnities for the receptors were
determined with receptors in the intact cells. Speciﬁcally,
binding aﬃnities for IGF-1R were determined with mouse
ﬁbroblasts transfected with human IGF-1R and with deleted
mouse IGF-1R according to Hexnerova et al.40 Binding
aﬃnities for IR-A were determined with human IR-A in
human IM-9 lymphocytes according to Vikova et al.49 Binding
aﬃnities for IR-B were determined with mouse ﬁbroblasts
transfected with human IR-B and with deleted mouse IGF-1R
according to Zakova et al.50 Representative binding curves of
analogues with the receptors are shown in Figure S1 (IGF-1R),
Figure S2 (IR-A), and Figure S3 (IR-B). The binding curve of
each analogue was determined in duplicate, and the ﬁnal
dissociation constant (Kd) was calculated from at least three (n
≥ 3) binding curves (Kd values), determined independently,
and compared to binding curves for IGF-1 or for IGF-2,
depending on the type of analogue.
The abilities of analogues to induce autophosphorylation of
IGF-1R in membranes of mouse ﬁbroblasts transfected with
human IGF-1R and with deleted mouse IGF-1R were
determined, as described by Machackova et al.51 The abilities
of analogues to induce autophosphorylation of IR-A in mouse
ﬁbroblasts transfected with human IR-A and with deleted
mouse IGF-1R were determined, as described by Krizkova et
al.52 Brieﬂy, the cells were stimulated in 24-well plates
(Schoeller) (4 × 104 cells per well) after being starved for 4
h in serum-free medium. The cells were stimulated with 10 nM
ligand (insulin, IGF-1, IGF-2, or analogues) for 10 min.
Stimulation was stopped by snap-freezing. Proteins were
routinely analyzed, using immunoblotting and horseradish
peroxidase-labeled secondary antibodies (Sigma-Aldrich). The
membranes were probed with anti-phospho-IGF-1Rβ
(Tyr1135/1136)/IRβ (Tyr1150/1151) (Cell Signaling Tech-
nology). The blots were developed using the SuperSignal West
Femto maximum sensitivity substrate (Pierce) and analyzed
using the ChemiDoc MP Imaging System (Bio-Rad). The
autophosphorylation signal density generated by each ligand on
a Western blot was expressed as the contribution of
phosphorylation relative to the IGF-1 (IGF-1R ﬁbroblasts)
respective human insulin (IR-A ﬁbroblasts) signal in the same
experiment. Mean ± standard deviation (SD) values were
calculated from four independent experiments (n = 4) and
compared to those of native IGF-1 or native IGF-2, depending
on the type of analogue. A representative example of an
immunoblot used for the evaluation of the abilities of analogues
to induce autophosphorylation of receptors is shown in Figure
S4.
The dose−response curves for human IGF-1 and [His45]-
IGF-1, [Asn45]-IGF-1, [Ala45]-IGF-1, [His46]-IGF-1, and
[Gln46]-IGF-1 analogues were also measured to determine
their EC50 values and their abilities to stimulate the
autophosphorylation of IGF-1R; here, the same methodology
as for the measurements at a single dose (above) was followed.
Log(agonist) versus response (variable slope) curve ﬁtting of
data was performed with GraphPad Prism 5. The representative
curves are shown in the Figure S5. The EC50 values (calculated
from at least three independent curves) are shown in the Table
S2.
The signiﬁcance of the changes in binding aﬃnities and in
the abilities of analogues to stimulate autophosphorylation was
calculated using the two-tailed t test.
■ RESULTS
Production of IGF-1 and IGF-2 Analogues. The
production of IGF-1 and IGF-2 was achieved by their
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recombinant expression in Escherichia coli as a fusion with an N-
terminal and cleavable His6-tagged GB1 protein (immunoglo-
bulin binding domain B1 of streptococcal protein-G), followed
by the cleavage of the fusion protein with TEV protease.
Recently, we used this strategy for the synthesis of IGF-2
analogues modiﬁed in the hormone’s C domain and possessing
an extra glycine residue at their N-terminus (position −1).40
Here, we modiﬁed the TEV cleavage site (see Materials and
Methods) and succeeded in producing native IGF-2 without
the additional Gly−1.
However, this strategy was not successful for IGF-1 because
of the proline residue at position 2 in IGF-1 (Figure 1), which
hampered TEV protease-mediated cleavage. Therefore, all
analogues of the hormone produced in this work have an
extra glycine residue (Gly−1) at the protein N-terminus that
enabled TEV protease cleavage of the precursor. The presence
of Gly−1 did not have any signiﬁcant eﬀect on the binding
properties of the IGF-1 derivative for either tested receptor
[IGF-1R or IR-A (Table 1 or 2, respectively)], and both native
IGF-1 and Gly−1-IGF-1 can be considered as equipotent.
Design of the First Series of Analogues. The ﬁrst series
of analogues was designed with the substitution of IGF-1 Asp45
with “insulin-inspired” His, Asn, and Ala, and a similar strategy
was applied for the replacement of IGF-1 Glu46 with His, Gln,
and Ala. The Asn45 and Gln46 mutations were also combined.
All planned IGF-1 analogues (Tables 1 and 2) were successfully
produced in quantities suﬃcient for their biological and
physicochemical characterization.
In parallel, similar mutations were designed for IGF-2 at
positions Glu44 and Glu45 that correspond to IGF-1 positions
45 and 46 (Figure 1). However, only one IGF-2 analogue,
[Gln45]-IGF-2, was made with a signiﬁcant yield that allowed
its characterization. All other IGF-2 analogues formed insoluble
precipitates after the TEV cleavage/folding steps.
IGF-1R Binding and Activation Properties of IGF-1
Analogues Modiﬁed at Positions 45 and 46, and the
[Gln45]-IGF-2 Analogue. The analogues were tested for their
binding to the IGF-1 receptor (IGF-1R) (Table 1), and their
binding data were compared with the abilities of the analogues
to induce autophosphorylation of the IGF-1R at a concen-
tration of 10 nM (Figure 3A). For human IGF-1 and [His45]-
IGF-1, [Asn45]-IGF-1, [Ala45]-IGF-1, [His46]-IGF-1 and
[Gln46]-IGF-1 analogues, we also determined EC50 values of
their abilities to stimulate autophosphorylation of IGF-1R
(Figure S5).
In general, the mutations did not dramatically alter the
binding characteristics of the analogues in comparison with
those of native IGFs. However, it can be noted that analogues
with mutations at site 45, [His45]-IGF-1, [Asn45]-IGF-1, and
[Ala45]-IGF-1, have signiﬁcantly reduced (29−60%) binding
aﬃnities for IGF-1R, with the lowest values being that of
[Ala45]-IGF-1.
The only successfully prepared IGF-2 analogue in this series,
[Gln45]-IGF-2, had reduced binding potency for IGF-1R
compared to that of native IGF-2 (Table 1) but activated IGF-
1R like native IGF-2 did (Figure 3A).
Relative EC50 values of IGF-1R stimulation by the selected
analogues were in good general agreement with their relative
ability to stimulate this receptor performed at a set ligand
concentration of 10 nM (Table S2). Hence, it appeared that the
autophosphorylation abilities of hormones determined at their
10 nM concentrations were good representations of their
properties, and as this approach substantially improved the time
and material economy of this extensive methodology, the
receptor activation abilities of the rest of the analogues were
measured at this set ligand concentration only. In general, no
major discrepancies between the IGF-1R binding and activation
properties of the analogues mutated at positions 45 and 46 of
IGF-1 and [Gln45]-IGF-2 were observed (Table 1 and Figure
3A). Some analogues, e.g., [His46]-IGF-1 and [Gln46]-IGF-1,
activated IGF-1R slightly less strongly than human IGF-1 did,
but their apparent higher binding aﬃnities for this receptor
were not statistically signiﬁcant. In contrast, [His45]-IGF-1,
[Asn45]-IGF-1, and [Ala45]-IGF-1 analogues activated IGF-1R
like human IGF-1 did, but their binding aﬃnities were
signiﬁcantly reduced. Therefore, although some minor
discrepancies could be observed here, any clear and major
antagonism, or receptor overstimulation, was not detected.
IR-A Binding and Activation Properties of IGF-1
Analogues Modiﬁed at Sites 45 and 46, and the
Table 1. IGF-1R Binding Aﬃnities of Native Hormones and
Analogues Reported in This Worka
analogue
Kd ± SD (nM) (n) for
the human IGF-1R in
mouse ﬁbroblasts
relative binding
aﬃnity for human
IGF-1R (%) relative
to that of human
IGF-1
human IGF-1 0.24 ± 0.05b (5) 100 ± 21
0.12 ± 0.01c (5) 100 ± 8
0.34 ± 0.12d (4) 100 ± 35
0.16 ± 0.06e (3) 100 ± 37
0.25 ± 0.03f (4) 100 ± 12
ﬁrst series of IGF-1 analogues
Gly−1-IGF-1 0.25 ± 0.02b (3) 96 ± 8
[His45]-IGF-1 0.39 ± 0.11c (4)*** 31 ± 9
[Asn45]-IGF-1 0.20 ± 0.07c (3)* 60 ± 21
[Ala45]-IGF-1 0.41 ± 0.27c (4)* 29 ± 19
[His46]-IGF-1 0.18 ± 0.04b (4) 133 ± 29
[Gln46]-IGF-1 0.18 ± 0.01b (3) 133 ± 7
[Ala46]-IGF-1 0.26 ± 0.11b (3) 92 ± 39
[Asn45,Gln46]-IGF-1 0.70 ± 0.28d (4) 49 ± 20
second series of IGF-1 analogues
[His49]-IGF-1 0.50 ± 0.23d (4) 68 ± 31
[His46,His49]-IGF-1 0.29 ± 0.17e (4) 55 ± 32
[Gln46,His49]-IGF-1 0.30 ± 0.09e (3) 53 ± 16
[Asn45,Gln46,His49]-
IGF-1
0.92 ± 0.04d (3)*** 37 ± 2
human IGF-2 2.3 ± 1.2f (3)* 10.9 ± 5.7
ﬁrst series of IGF-2 analogues
[Gln45]-IGF-2 2.9 ± 0.3e (3)* 5.5 ± 0.6
second series of IGF-2 analogues
[His48]-IGF-2 0.88 ± 0.23e (3) 18.2 ± 4.7
[Gln45,His48]-IGF-2 0.89 ± 0.05e (3) 18.0 ± 1.0
aThe values of Kd and relative binding aﬃnities [relative receptor
binding aﬃnity deﬁned as (Kd of human IGF-1)/(Kd of analogue) ×
100] of human IGF-1, IGF-2, and analogues were determined for
human IGF-1R in mouse ﬁbroblasts. All IGF-1 analogues have an extra
glycine residue at the N-terminus (Gly−1). n is the number of
replicates. Asterisks indicate that binding of a particular ligand to IGF-
1R diﬀers signiﬁcantly (*p < 0.05; ***p < 0.001) from the eﬀect of
IGF-1 in the case of IGF-1 analogues or diﬀers signiﬁcantly from the
eﬀect of IGF-2 in the case of IGF-2 analogues. Binding of native IGF-2
is related to that of human IGF-1. bRelative to the human IGF-1 Kd
value of 0.24 ± 0.05 (n = 5). cRelative to the human IGF-1 Kd value of
0.12 ± 0.01 (n = 5). dRelative to the human IGF-1 Kd value of 0.34 ±
0.12 (n = 4). eRelative to the human IGF-1 Kd value of 0.16 ± 0.06 (n
= 3). fRelative to the human IGF-1 Kd value of 0.25 ± 0.03 (n = 4).
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[Gln45]-IGF-2 Analogue. The IGF-1 analogues of the ﬁrst
series have binding aﬃnities for IR-A similar to that of native
IGF-1 (Table 2), and their IR-A activation properties (Figure
3B) are again in general agreement with the properties of native
IGF-1.
The [Gln45]-IGF-2 analogue binds IR-A signiﬁcantly more
strongly (≤20% of the binding aﬃnity of native human insulin)
than the native IGF-2 that has only 8% of the binding aﬃnity of
human insulin. However, the IR-A enhanced aﬃnity of this
analogue was not fully translated into its activation potency that
is similar to the activation potency of native IGF-2.
Design of the Second Series of IGF-1 and IGF-2
Analogues. The ThrA8His substitution in insulin increases
the potency for IR-A;41−46 hence, it was also used by Whittaker
et al.37 to increase the level of IR binding of A4/A5-modiﬁed
insulins, without eliminating their antagonistic properties.
Therefore, we probed a similar strategy for the IGF-1 and
Table 2. IR-A Receptor Binding Aﬃnities of Native
Hormones and Analogues Reported in This Worka
analogue
Kd ± SE (nM) (n) for
human IR-A in IM-9
lymphocytes
relative binding
aﬃnity for human
IR-A (%) relative to
that of human
insulin
human insulin 0.25 ± 0.05b (5) 100 ± 20
0.27 ± 0.02c (5) 100 ± 7
0.18 ± 0.01d (4) 100 ± 6
0.32 ± 0.09e (4) 100 ± 28
0.30 ± 0.13f (5) 100 ± 43
human IGF-1 23.7 ± 11.5b (3)*** 1.1 ± 0.5
ﬁrst series of IGF-1 analogues
Gly−1-IGF-1 35.6 ± 11.9b (3) 0.7 ± 0.2
[His45]-IGF-1 20.1 ± 7.8c (4) 1.3 ± 0.5
[Asn45]-IGF-1 19.3 ± 9.6c (4) 1.4 ± 0.7
[Ala45]-IGF-1 17.6 ± 9.7c (3) 1.5 ± 0.8
[His46]-IGF-1 6.6 ± 1.2d (3) 2.7 ± 0.5
[Gln46]-IGF-1 18.1 ± 3.6d (3) 1.0 ± 0.2
[Ala46]-IGF-1 14.0 ± 1.9d (3) 1.3 ± 0.2
[Asn45,Gln46]-IGF-1 17.5 ± 8.4e (3) 1.8 ± 0.9
second series of IGF-1 analogues
[His49]-IGF-1 6.7 ± 2.4e (3)* 4.8 ± 1.7
[His46,His49]-IGF-1 3.4 ± 1.7e (3)* 9.4 ± 4.7
[Gln46,His49]-IGF-1 7.5 ± 4.1e (3)* 4.3 ± 2.3
[Asn45,Gln46,His49]-
IGF-1
5.5 ± 2.5f (4)*** 5.5 ± 2.5
human IGF-2 2.9 ± 0.2b (3)*** 8.6 ± 0.6
ﬁrst series of IGF-2 analogues
[Gln45]-IGF-2 1.6 ± 0.3e (3)** 20 ± 3.8
second series of IGF-2 analogues
[His48]-IGF-2 0.54 ± 0.13e (3)*** 59.3 ± 14.3
[Gln45,His48]-IGF-2 0.65 ± 0.12f (3)*** 46.2 ± 8.5
aThe values of Kd and relative binding aﬃnities [relative receptor
binding aﬃnity deﬁned as (Kd of human insulin)/(Kd of analogue) ×
100] of human insulin, IGF-1, IGF-2, and analogues were determined
for human IR-A in human IM-9 lymphocytes. All IGF-1 analogues
have an extra glycine residue at the N-terminus (Gly−1). n is the
number of replicates. Asterisks indicate that binding of a particular
ligand to IR-A diﬀers signiﬁcantly (*p < 0.05; **p < 0.01; ***p <
0.001) from the eﬀect of IGF-1 in the case of IGF-1 analogues or
diﬀers signiﬁcantly from the eﬀect of IGF-2 in the case of IGF-2
analogues. Binding of native IGF-2 is related to that of human insulin.
bRelative to the human insulin Kd value of 0.25 ± 0.05 (n = 5).
cRelative to the human insulin Kd value of 0.27 ± 0.02 (n = 5).
dRelative to the human insulin Kd value of 0.18 ± 0.01 (n = 4).
eRelative to the human insulin Kd value of 0.32 ± 0.09 (n = 4).
fRelative to the human insulin Kd value of 0.30 ± 0.13 (n = 5).
Figure 3. Relative abilities to activate (A) IGF-1R and (B) IR-A of
human insulin (HI), human IGF-1, human IGF-2, and IGF-1 and IGF-
2 analogues. All IGF-1 analogues contain a glycine residue at position
−1. Relative abilities to activate receptors were determined with 10 nM
ligands after a 10 min stimulation. Mean ± SD values were calculated
from four independent experiments (n = 4). In panel A, the
experimental values are related to the biological activity of human
IGF-1. In panel B, the experimental values are the biological activity of
human insulin (HI). Asterisks indicate that induction of autophos-
phorylation of a particular receptor induced by a ligand diﬀers
signiﬁcantly (*p < 0.05; **p < 0.01; ***p < 0.001) from the eﬀect of
IGF-1 in the case of IGF-1 analogues or diﬀers signiﬁcantly from the
eﬀect of IGF-2 in the case of IGF-2 analogues. In panel A, the
signiﬁcance of the eﬀect of native IGF-2 (asterisks) is related to human
IGF-1 and in panel B to human insulin. In panel B, the signiﬁcance of
the eﬀect of native IGF-1 (asterisks) is related to human insulin.
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IGF-2 analogues, which both have phenylalanine at the insulin
A8 equivalent 49 and 48 sites, respectively (Figure 1).
First, the [His49]-IGF-1 analogue was made to investigate
the eﬀect of this single mutation. Subsequently, it was
combined with His or Gln single mutations at site 46 and
with Asn45/Gln46 double mutations, as well.
In the case of IGF-2, the single mutation [His48]-IGF-2
analogue was made, which was extended for Gln45 mutation, as
well, as it was here the only successful substitution of IGF-2 in
the ﬁrst series.
IGF-1R Binding and Activation Properties of the
Second Series of IGF-1 and IGF-2 Analogues. All new
IGF-1 mutations have fairly minor, or no signiﬁcant, eﬀects on
IGF-1R binding aﬃnities and activation capabilities, with only
the [Asn45,Gln46,His49]-IGF-1 triple mutant having signiﬁ-
cantly less aﬃnity (37%) for the IGF-1R than native IGF-1 has
but with native IGF-1-like autophosphorylation activation
ability (Table 1 and Figure 3A).
A similar trend was observed for both new IGF-2 analogues,
[His48]-IGF-2 and [Gln45,His48]-IGF-2, the IGF-1R binding
and activation abilities of which were similar to those of native
IGF-2.
IR-A Binding and Activation Properties of the Second
Series of IGF-1 and IGF-2 Analogues. The IR-A-related
properties of the analogues contrast with their IGF-1R aﬃnities
and binding eﬀects. It seems that the presence of His49
strongly enhances (4−9-fold) the IR-A binding aﬃnity of new
IGF-1 analogues (Table 2), in comparison to that of native
IGF-1. Moreover, His49-containing IGF-1 analogues do not
show any IR-A antagonism, as their capabilities to activate this
receptor are superior, or similar, to those of native IGF-1
(Figure 3B).
IR-A binding aﬃnities of two new IGF-2 analogues carrying a
His48 mutation are also very (5−7-fold) enhanced, in
comparison with those of native IGF-2. Remarkably, both of
these analogues bind IR-A with subnanomolar aﬃnities, which
make them half-equipotent with human insulin with respect to
this IR isoform (Table 2). Moreover, the IR-A activation
abilities of these two IGF-2 analogues are also very high, with a
potency similar to that of human insulin (Figure 3B).
In general, the levels of activation of IR-A by insulin, IGF-1,
IGF-2, and analogues determined at 10 nM (Figure 3B)
correspond well to their respective binding aﬃnities for this
receptor (Table 2), and they are in a good agreement with the
levels of IR-A autophosphorylation induced by 10 nM insulin,
IGF-1, and IGF-2 in dose−response curves reported recently
by Andersen et al.53
IR-B Binding Properties of [His49]-IGF-1 and
[Gln45,His48]-IGF-2 Analogues. The outstanding enhance-
ment of IR-A binding aﬃnities exhibited by the His49/His48
IGF-1/2 mutants prompted their characterization toward the
IR-B isoform, as well. For this purpose, we tested two
representative analogues, [His49]-IGF-1 and [Gln45,His48]-
IGF-2, for their binding aﬃnity for IR-B (Table 3). Most
interestingly, we found that the IR-B binding aﬃnity of
[Gln45,His48]-IGF-2 is ∼8 times higher than that of human
IGF-2 and that the binding of [His49]-IGF-1 to this IR isoform
is ∼3 times stronger than that of native IGF-1. These mutations
did not considerably aﬀect the IR isoform speciﬁcity of the
analogues because their IR-A binding enhancing eﬀects were
similar (5 times for [Gln45,His48]-IGF-2 and ∼4 times for
[His49]-IGF-1).
■ DISCUSSION
All 11 planned IGF-1 analogues were successfully produced,
but only three IGF-2 analogues ([Gln45]-IGF-2,
[Gln45,His49]-IGF-2, and [His49]-IGF-2) were made, as the
other analogues of this hormone formed insoluble precipitates
during the folding steps of their puriﬁcation. As Whittaker et
al.37 successfully prepared HisA4, AlaA4, and HisA5 insulins,
the severe aggregation of some IGF-2 analogues indicates
diﬀerent folding mechanisms of these hormones, underlining
the importance of IGF-2 Glu44/45 for its eﬃcient assembly.
However, a more extensive mutagenesis, especially of the IGF-2
Glu44 site, is needed for an unambiguous conﬁrmation of the
folding-related importance of these side chains.
In general, the majority of mutations performed here have a
rather minor impact on the IGF-1R binding aﬃnities of IGF-1
and IGF-2 analogues (Table 1). However, diﬀerent trends may
be observed for the His mutation at position 48 of IGF-2 that
enhances its IGF-1R aﬃnity, while the His mutation at IGF-1
equivalent site 49 has an opposite eﬀect. This may indicate that
the natures of interactions of IGF-1 and IGF-2 with IGF-1R are
diﬀerent, and speciﬁc, for IGF-1 and IGF-2 at their sites 49 and
48, respectively; i.e., the equivalent amino acids at these sites do
not interact with the IGF-1R in the same fashion.
Interestingly, the mutations of sites 49 and 48 in IGF-1 and
IGF-2, respectively, yielded analogues of these hormones with
much more signiﬁcant, and interesting, changes in their IR-A
binding aﬃnities (Table 2) than in their IGF-1R binding/
activation properties. Here, both IGF-1 and IGF-2 analogues
with His at sites 49 and 48, respectively, are much better IR-A
binders than their native forms. The data presented here
indicate that this eﬀect can be attributed mainly to the isolated
impact of His49, or His48, as the simultaneous mutations at
these sites and of residues 45 and 46 in IGF-1 (or residue 45 in
IGF-2) do not generate any additional, signiﬁcant positive
properties toward IR-A.
It has been shown that the ThrA8His mutation doubles or
triples the insulin IR-A binding aﬃnity,41−45 and Whittaker et
al.37 used such a mutation to restore IR binding aﬃnity of the
less active A4 and A5 insulin mutants. Here, similar mutations
enhanced 4−9-fold the IR-A binding aﬃnities of the IGF-1
analogues and 5−7-fold the binding aﬃnities of the IGF-2
Table 3. IR-B Receptor Binding Aﬃnities of Native
Hormones and [His49]-IGF-1 and [Gln45,His48]-IGF-2
Analogues Reported in This Worka
analogue
Kd ± SE (nM) (n) for
human IR-B in mouse
ﬁbroblasts
relative binding aﬃnity for
human IR-B (%) relative to that
of human insulin
human insulin 0.50 ± 0.31 (5) 100 ± 62
human IGF-1 224 ± 16 (4)b*** 0.22 ± 0.02
[His49]-IGF-1 72.3 ± 12.0 (3)*** 0.69 ± 0.11
human IGF-2 35.5 ± 5.6 (4)b*** 1.4 ± 0.2
[Gln45,His48]-
IGF-2
4.3 ± 1.7 (4)** 11.6 ± 4.6
aThe values of Kd and relative binding aﬃnities [relative receptor
binding aﬃnity deﬁned as (Kd of human insulin)/(Kd of analogue) ×
100] of human insulin, IGF-1, IGF-2, and analogues were determined
for human IR-B in mouse ﬁbroblasts. n is the number of replicates.
Asterisks indicate that the binding a particular ligand to IR-B diﬀers
signiﬁcantly (**p < 0.01; ***p < 0.001) from the eﬀect of IGF-1 in
the case of an IGF-1 analogue or diﬀers signiﬁcantly from the eﬀect of
IGF-2 in the case of an IGF-2 analogue. The binding of native IGF-1
and IGF-2 is relative to that of human insulin. bFrom ref 52.
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analogues, compared to the aﬃnities of the native hormones.
The positive eﬀect of His49 and His48 mutations on IR-A
binding is similar for both IGF-1 and IGF-2, and to the best of
our knowledge, these analogues are the strongest IGF-1-like
and IGF-2-like binders of the IR-A receptor isoform thus far
reported. In particular, the high IR-A binding aﬃnity of
[His48]-IGF-2 is remarkable, as only this single mutation was
suﬃcient to generate an analogue with ∼50% insulin-like
aﬃnity for the IR-A. Moreover, we found that the IR-A binding
aﬃnity enhancing eﬀect of His49 and His48 is manifested with
the IR-B, as well, because the [His49]-IGF-1 analogue is an ∼3-
fold stronger IR-B binder than native IGF-1 is and, remarkably,
[Gln45,His48]-IGF-2 binds IR-B ∼8-fold more strongly than
native IGF-2 does, having almost 12% of the binding aﬃnity of
human insulin. Therefore, it seems that [His49]-IGF-1 and
[Gln45,His48]-IGF-2 analogues are the strongest reported
IGF-1-like and IGF-2-like IR-B binders. The exceptional
binding “promiscuity” of [His48]-IGF-2 toward IR-A and IR-
B is outstanding and reveals how easily IGF-2 can be converted
into a high-aﬃnity ligand for IR receptors. This “ubiquitous”
hormonal property of IGF-2 may evoke questions about its
evolutionary origins, and it could be hypothesized that IGF-2
resembles the hypothetical evolutionary hormonal ancestor of
the insulin/IGF axis more closely than insulin or IGF-1 does.
It is generally accepted that insulin and IGFs interact with
their receptors through two main binding sites, sites 1 and 2 in
the hormones, and sites 1′ and 2′, respectively, in the
receptors.54 The nature of the interactions of site 1 in insulin
and IGF-1 with site 1′ in IR-A and IGF-1R is relatively well
characterized in the crystal structures of their complexes
(Figure 2). However, structural details about hormone site 2−
receptor site 2′ interactions are still missing, and insulin amino
acids, which determine its site 2, ThrA8, IleA10, SerA12,
LeuA13, GluA17, HisB10, GluB13, and LeuA17, have been
suggested through extensive mutagenesis studies.54
The diﬀerent eﬀects of His mutations in IGFs on binding
aﬃnities for IR-A, IR-B, and IGF-1R could mean that amino
acids at positions 49 (IGF-1) and 48 (IGF-2) are engaged with
signiﬁcantly diﬀerent protein environments in complexes with
IR and IGF-1R. Although it is expected that Phe49 in IGF-1,
Phe48 in IGF-2, and ThrA8 in insulin (all at site 2 of the
hormones) interact with 2′ sites of the receptors, the possibility
that the increase in the level of IR-A binding of [His48]-IGF-2
and [His49]-IGF-1 analogues may also result from an
enhancement of some contacts with elements of IR site 1′
cannot be excluded (Figure 2). For example, His49 and His48
of IGFs could form double direct, or water-mediated, hydrogen
bonds with Asp707 in the IR α-CT segment and with Asn694
in IGF-1R, as well (Figure 2A), while insulin native ThrA8 is
too short for such interactions. It is also possible that the native
Phe49 and Phe48 in IGFs can contribute only some weak van
der Waals intramolecular contacts with the IGF-1 Cys48−Cys6
disulﬁde bond and Val44 (IGF-2 Cys47−Cys9 and Val43).
Hence, His49 and His48 mutations may provide much stronger
directional contacts with both receptor sites (1′ and 2′), which
seem to be more favorable for IR-A rather than for IGF-1R.
In general, our new IGF-1 and IGF-2 analogues did not show
any considerable reversed trends between their aﬃnities and
receptor activation abilities (Tables 1 and 2, Figure 3A,B, and
Figure S5). Therefore, the previously observed signiﬁcant
disproportionate binding and activation of insulin analogues
mutated at A4 and A8 (ref 37) are probably speciﬁc and limited
for insulin−IR interactions. It is possible that a diﬀerent
receptor activation behavior of insulin and IGF-1 (IGF-2)
analogues mutated at positions A4 and A8 and positions 45, 46,
and 49 (positions 45 and 48), respectively, may result from
diﬀerent interactions with speciﬁc amino acids at 2′ sites of the
IR that are currently not yet determined (see the preceding
discussion). Such dissimilar natures of hormone−receptor
interfaces may lead to non-equivalent receptor binding
mechanisms (as previously pertinently mentioned by Sohma
et al. in ref 55) and their subsequent diﬀerent impacts on signal
transduction through the receptors and, ultimately, the
activation of their tyrosine kinases.
As indicated above, some trends observed in the analogues
described here can be also corroborated by the phylogeny of
insulin-related hormones. For example, the insulin ThrA8-
containing A8−A10 region is considered as a hypervariable part
of this hormone because of its signiﬁcant sequence diﬀerences
in mammals.56 However, the A8 site is the most invariable
amino acid in the A8−A10 triad. For example, the well IR-A
tolerated (87% binding aﬃnity of HI) AlaA8 occurs in cattle,
sheep, and goat insulin.57 Although there is no mammalian
insulin with His at site A8, this amino acid is frequently present
at that position in ﬁsh, frog, and bird insulins.56 Also, HisA8
was proposed to be responsible for an ∼5-fold higher binding
aﬃnity of chicken insulin for IR in human lymphocytes.41
Herring at al.46 proposed that it is possible that a “lower-
aﬃnity” ThrA8 site in mammals emerged from the evolutionary
optimization of the insulin receptor kinetics, which requires a
decrease in insulin binding aﬃnity in mammals that is dictated
by a diﬀerent route of insulin delivery. In more ancient
vertebrates like birds, insulin is secreted diﬀerently, by the
kidney, which leads to rapid metabolic changes.46 However, in
mammals, the pancreas-to-liver portal vein-mediated pathway is
the primary direction of insulin. In humans, the liver is the main
glycemic-response organ with >90% “metabolic” IR-B isoform
and where insulin inhibits gluconeogenesis and glycogenolysis
before reaching the peripheral tissues. It may be postulated
then that to ensure an optimum liver:body distribution of
insulin its IR binding aﬃnity needs to be reduced in mammals,
to achieve a more systemic glycemic response.46
All known naturally occurring variants of IGF-1 and IGF-2
(including avian) maintain Phe at their insulin ThrA8-
corresponding sites 49 and 48, respectively. Therefore, it may
be assumed that the IR high-aﬃnity inducing HisA8 mutation
in insulin selected upon evolution was required for only rapid
and immediate metabolic eﬀects of insulin and was not needed
for slower and long-lasting growth eﬀects of IGFs. However, a
high sensitivity of both IGFs to acquisition of His48 and His49
mutations may reﬂect their common evolutionary origins with
insulin.
It will be interesting to further explore the ﬁndings of this
report by testing speciﬁc amino acid substitutions at the A8 site
of insulin, to maintain its potent IR binding but to decrease its
aﬃnity for IGF-1R. Such analogues could be useful for the safer
treatment of diabetes, as some currently administered insulin
derivatives (e.g., glargine) show higher IGF-1R aﬃnity and
hence, potentially, an increased risk of cancer.58−62
In summary, as we showed that respective positions in insulin
and IGFs lead to non-equivalent IR-A and IGF-1R binding
mechanisms of these hormones, this work opens new directions
for the rational engineering of the hormonal components of the
insulin/IGF system.
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■ CONCLUSIONS
We systematically investigated the receptor binding and
receptor activation properties of IGF-1 and IGF-2 analogues
modiﬁed at positions 45, 46, and 49 (IGF-1) and at positions
44, 45, and 48 (IGF-2). These modiﬁcations did not
signiﬁcantly aﬀect the IGF-1R binding of these hormones.
However, analogues with the Phe49His mutation in IGF-1 and
the Phe48His mutation in IGF-2 have remarkably enhanced
binding aﬃnities for both IR-A and IR-B isoforms of the insulin
receptor. Here, IGF-1 analogues with His at position 49 possess
approximately 5−9% of IR-A, and [His49]-IGF-1 possess
∼0.7% of the IR-B binding aﬃnity of human insulin. Moreover,
IGF-2 analogues with His at position 48 are approximately half-
equipotent to human insulin in binding to IR-A, and
[Gln45,His48]-IGF-2 has almost 12% of the insulin binding
aﬃnity for this “metabolic” isoform. The binding aﬃnities of all
analogues are in general proportionate to their abilities to
activate IR and IGF-1R without any important discrepancies.
This study revealed that IR and IGF-1R can contain speciﬁc
sites, probably parts of so-called receptors’ sites 2′, which can
interact diﬀerently with insulin and with IGFs. These ﬁndings
shed light on new, possible directions of rational engineering of
insulin and IGFs toward more selective and receptor-speciﬁc
analogues with medical applications.
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